International Society for Cell and Gene Therapy of Cancer (ISCGT) annual meeting: Conference overview and introduction to the symposium papers

Cancer Immunology, Immunotherapy

Volumn 55, Issue 11, 2006, Pages 1406-1411

  Guinn, Barbara Ann ^a   Norris, James S ^b   Huang, LaiQiang ^c   Farzaneh, Farzin ^a   Kasahara, Noriyuki ^d   Deisseroth, Albert B ^e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c TSINGHUA UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

Cancer research; Gene therapy; Immunotherapy; International Society for Cell and Gene Therapy of Cancer; Meeting report

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; B7 ANTIGEN; CAPSID PROTEIN; CAPSID PROTEIN IX; CD4 ANTIGEN; CD40 LIGAND; COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GENDICINE; GLUCOSE REGULATED PROTEIN 94; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MIDKINE; ONCOLYTIC VIRUS; PARVOVIRUS VECTOR; PRODRUG; PROTEIN P53; RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR VACCINE; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; FEVER; GASTROINTESTINAL SYMPTOM; GENE; GENE THERAPY; HALF LIFE TIME; HEAD AND NECK CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYDRODYNAMICS; LARYNX CARCINOMA; LIVER CELL CARCINOMA; MEDICAL SOCIETY; MELANOMA; NASOPHARYNX CARCINOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TPO GENE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 33746898144     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0187-x     Document Type: Conference Paper

References (12)

1. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR (2002) Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 62:6165-6171
2. Chan L, Hardwick NR, Guinn BA, Darling D, Gaken J, Galea-Lauri J, Ho AY, Mufti GJ, Farzaneh F (2006) An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother 55:1017-1024
3. Chandrashekran A, Gordon MY, Darling D, Farzaneh F, Casimir C (2004) Growth factor displayed on the surface of retroviral particles without manipulation of envelope proteins is biologically active and can enhance transduction. J Gene Med 6:1189-1196
4. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA (1994) Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86:1458-1462
5. Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J, Laudani L, Grill J, Giaccone G, Vandertop WP, Gerritsen WR, van Beusechem VW (2004) Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res 64:5753-5759
6. Geoerger B, van Beusechem VW, Opolon P, Morizet J, Laudani L, Lecluse Y, Barrois M, Idema S, Grill J, Gerritsen WR, Vassal G (2005) Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med 7:584-594
7. Gershon RK, Cohen P, Hencin R, Liebhaber SA (1972) Suppressor T cells. J Immunol 108:586-590
8. Guinn BA, Norris JS, Farzaneh F, Deisseroth AB (2006) International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China. Cancer Gene Ther (in press)
9. Löhr JM, Kröger J-C, Hoffmeyer A, Freund M, Hain J, Holle A, Knöfel WT, Liebe S, Nizze H, Renner M, Saller R, Karle P, Müller P, Wagner T, Hauenstein K, Salmons B, Günzburg WH (2003) Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial. Cancer Therapy 1:121-131
10. Peng Z (2005) Current status of Gendicine in China: Recombinant human Ad-p53 agent for the treatment of cancer. Hum Gene Therapy 16:1016-1027
11. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915
12. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T (1985) Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 161:72-87